title: Oligotide, a new single-stranded oligodeoxyribonucleotide, preserves postsynaptic beta-adrenergic and cholinergic receptor functions in rabbit hearts after acute infarction.
abstract: Acute myocardial infarction was induced in New Zealand male albino rabbits. 3 days after surgery, the mortality rate and plasma CPK activity were reduced by 64% and 66% respectively by intravenous infusion of Oligotide (32 mg/kg/h for 6h), a single-stranded oligodeoxyribonucleotide of mammalian origin. Perfused hearts, obtained from Oligotide-treated rabbits 3 days after surgery, showed a strength of contraction in the range of that of hearts of sham-operated animals and an ameliorated postsynaptic beta-adrenergic and cholinergic receptor function. In addition, in these hearts, "ex vivo" treatment with Oligotide resulted in almost complete preservation of both adrenergic and cholinergic responses to their specific agonists. These data suggest that Oligotide by protecting the hearts from the ischemic damage and possibly by restricting left ventricular tissue necrosis may have normalized the biological responses of this organ to isoproterenol and preserved the integrity of coronary endothelial-dependent relaxant function.
authors.affiliation: Department of Pharmacology, Chemotherapy and Medical Toxicology, University of Milan, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Rossoni
authors.forename: F
authors.initials: F
authors.lastname: Berti
authors.forename: M
authors.initials: M
authors.lastname: Berti
authors.forename: M
authors.initials: M
authors.lastname: Bernareggi
authors.forename: F
authors.initials: F
authors.lastname: Trento
authors.forename: R
authors.initials: R
authors.lastname: Porta
authors.forename: R
authors.initials: R
authors.lastname: Pescador
authors.forename: L
authors.initials: L
authors.lastname: Ferro
mesh_terms: D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D004353:Drug Evaluation, Preclinical; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism; D011464:Epoprostenol / Q000096:biosynthesis*; D007262:Infusions, Intravenous; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D009838:Oligodeoxyribonucleotides / Q000494:pharmacology / Q000627:therapeutic use*; D017777:Parasympathetic Fibers, Postganglionic / Q000503:physiopathology*; D011817:Rabbits; D011943:Receptors, Adrenergic, beta / Q000502:physiology*; D011950:Receptors, Cholinergic / Q000502:physiology*; D013268:Stimulation, Chemical; D017779:Sympathetic Fibers, Postganglionic / Q000503:physiopathology*; D016277:Ventricular Function, Left / Q000187:drug effects
chemical_list: D009838:Oligodeoxyribonucleotides; D011943:Receptors, Adrenergic, beta; D011950:Receptors, Cholinergic; D011464:Epoprostenol; D007545:Isoproterenol; D000109:Acetylcholine